WaferGen Biosystems, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited) | |||||||
Three Months Ended March 31, | |||||||
2010 | 2009 | ||||||
(Restated) | |||||||
Revenue | $ | 389,785 | $ | 41,838 | |||
Cost of Revenue | 135,855 | 15,832 | |||||
Gross margin | 253,930 | 26,006 | |||||
Operating expenses: | |||||||
Sales and marketing | 249,806 | 135,848 | |||||
Research and development | 1,542,268 | 959,888 | |||||
General and administrative | 1,043,905 | 732,166 | |||||
Total operating expenses | 2,835,979 | 1,827,902 | |||||
Operating loss | (2,582,049) | (1,801,896) | |||||
Other income and (expenses): | |||||||
Interest income | 5,158 | 3,072 | |||||
Interest expense | (607) | (2,832) | |||||
Unrealized gain (loss) on fair value of warrants, net | (1,886,692) | 13,743 | |||||
Miscellaneous income (expense) | (65,075) | 23,856 | |||||
Total other income and (expenses) | (1,947,216) | 37,839 | |||||
Net loss before provision for income taxes | (4,529,265) | (1,764,057) | |||||
Provision for income taxes | — | — | |||||
Net loss | (4,529,265) | (1,764,057) | |||||
Cumulative effect of reclassification of warrants | — | — | |||||
Accretion on Redeemable Convertible Preference Shares in Subsidiary | (65,523) | (35,000) | |||||
Accretion on Series B Preferred Stock | — | — | |||||
Net loss applicable to common stockholders | $ | (4,594,788) | $ | (1,799,057) | |||
Net loss per share - basic and diluted | $ | (0.14) | $ | (0.07) | |||
Shares used to compute net loss per share - basic and diluted | 33,503,316 | 24,830,932 | |||||
